Tag:

HPV

Latest Headlines

Latest Headlines

Gene editing method kills cervical cancer cells

Using a gene-editing method, investigators were able to delete certain genes in the human papillomavirus, prompting cancer-causing cells to self-destruct. The antiviral technique could be replicated to target other DNA-based viruses like hepatitis B and herpes simplex, researchers say.

Merck aims to boost HPV vaccination rates amid lagging numbers

Though Merck's Gardasil tops the company's best-selling vaccines list and has already achieved blockbuster sales, the drug giant has a long way to go if it wants to boost U.S. immunization rates against human papillomavirus.

No link between Merck's Gardasil and blood clots, study says

Worries over Gardasil's safety are just one of the issues that have hampered uptake of Merck's best-selling vaccine for HPV. But now, a study published in JAMA says patients need not worry about an increased risk of deadly blood clots.

Merck, Sanofi JV wins anal cancer indication for Gardasil in EU

Gardasil may be the No. 2-selling vaccine in the world, but its marketers have struggled against a variety of barriers to get it where they want it in terms of uptake. Now, a new anal cancer indication in Europe may help with that goal.

GAVI nets $50M for Merck's Gardasil, GSK's Cervarix

Back in 2012, the GAVI Alliance announced plans to help immunize 30 million girls in 40 countries with HPV vaccines by 2020. Wednesday, the Children's Investment Fund Foundation chipped in toward that goal with a $25 million investment that will be matched through the U.K.'s Department of International Development.

Provista broadens ASU cancer biomarker licensing deal

New York's Provista Diagnostics expanded a licensing deal for biomarker and autoantibody technology developed at Arizona State University--concepts first spotted at Harvard Medical School and the Dana-Farber Cancer Institute.

Roche's HPV test gets FDA approval for primary cervical cancer screen

Roche has won FDA approval for its HPV test used for primary screening of cervical cancer. The regulatory nod is expected to increase the company's profile in the U.S. and grow its 20% share of the global diagnostics markets.

Cepheid's 2014 Q1 produced Dx sales hikes but also more losses

Cepheid booked much higher sales during its fiscal 2014 first quarter and successfully launched new HPV and norovirus molecular diagnostic tests outside of the U.S. But the California company faced a net loss as it dealt with higher overall costs and continued to work through restructuring.

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi--who market the HPV vaccine in Europe through joint venture Sanofi Pasteur MSD--will see the number of shots per patient fall.

Merck, Sanofi hope for sales expansion with two-dose Gardasil switch

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi will see the number of shots per patient fall. But that doesn't mean they'll necessarily take a sales hit, with the move potentially expanding overall access and providing a bump both drugmakers could use.